Symbicort pMDI with spacer device + Symbicort pMDI without spacer device

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Study is Being Conducted in Healthy Volunteers

Conditions

Study is Being Conducted in Healthy Volunteers

Trial Timeline

Nov 4, 2016 → Mar 27, 2017

About Symbicort pMDI with spacer device + Symbicort pMDI without spacer device

Symbicort pMDI with spacer device + Symbicort pMDI without spacer device is a phase 1 stage product being developed by AstraZeneca for Study is Being Conducted in Healthy Volunteers. The current trial status is completed. This product is registered under clinical trial identifier NCT02934607. Target conditions include Study is Being Conducted in Healthy Volunteers.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02934607Phase 1Completed

Competing Products

20 competing products in Study is Being Conducted in Healthy Volunteers

See all competitors
ProductCompanyStageHype Score
Insulin Aspart + NovoRapid® Penfill®GEROPHARMPre-clinical
15
RinGlar® + Lantus®GEROPHARMPre-clinical
15
GP-40081 + NovoMix® 30 Penfill®GEROPHARMPre-clinical
15
Insulin Lispro Mix 25 + Humalog® Mix 25GEROPHARMPre-clinical
15
Insulin Lispro + Humalog®GEROPHARMPre-clinical
15
Clocortolone PivalateSun PharmaceuticalPhase 1
33
HetrombopagJiangsu Hengrui MedicinePhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
selumetinib 75mg single doseAstraZenecaPhase 1
33
AnifrolumabAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
AZD4635 + FluvoxamineAstraZenecaPhase 1
33
AZD0292 + PlaceboAstraZenecaPhase 1
33
D961S + Esomeprazole + Buffered acetylsalicylic acidAstraZenecaPhase 1
33
AZD8566 + AZD8566 IV carbon labelledAstraZenecaPhase 1
33
D961H Sachet 20 mg + D961H HPMC capsule 20 mgAstraZenecaPhase 1
33
D961H + OmeprazoleAstraZenecaPhase 1
33
Rapamycin + Everolimus + PrednisoneNovartisApproved
85
LEE011NovartisPhase 2
52
EC-MPSNovartisPhase 3
77